

ECS Botanics Holdings Ltd (ASX:ECS)



ASX Announcement

7 July 2025

ECS Botanics to support UWA clinical trial investigating medicinal cannabis for obstructive sleep apnoea

Highlights:

- ECS to supply its Avani THC10 Softgel Capsules to support a clinical trial led by the University of Western Australia's Centre for Sleep Science
- The trial will assess the effect of 10mg THC on obstructive sleep apnoea (OSA) severity, underlying physiological mechanisms and next-day cognitive performance
- ECS continues to support academic research aimed at clinically validating the therapeutic potential of medicinal cannabis

ECS Botanics Holdings Ltd (ASX: ECS) ("ECS" or the "Company"), a leading medicinal cannabis company, is pleased to announce its support for an upcoming investigator-led clinical trial by the Centre for Sleep Science at the University of Western Australia. The trial, registered on the Australian New Zealand Clinical Trials Registry (ACTRN12624000572549), will assess the therapeutic potential of medicinal cannabis in patients with clinically significant obstructive sleep apnoea (OSA).

Under the trial protocol, ECS will provide its Avani THC10 product for use as the investigational treatment. Avani THC10 capsules are part of ECS's premium product suite prescribed to patients and is manufactured to GMP standards.

This randomised, double-blind, controlled trial targets the enrolment of 24 participants and is expected to run through 2025. It will examine the impact of 10mg of THC on OSA severity and contributing physiological mechanisms, along with psychomotor and cognitive outcomes. Recruitment is anticipated to commence in July, 2025.

Nan-Maree Schoerie, Managing Director of ECS Botanics, commented:

"We are proud to support academic and medical research that helps explore the therapeutic potential of medicinal cannabis. Trials like this one are vital to building the evidence base that informs prescribing decisions. The outcome of these studies can help to validate the role that ECS's products can play in improving patient outcomes. As a company grounded in science, sustainability and transparency, we welcome the opportunity to contribute to rigorous clinical work."

ECS remains committed to working with researchers, clinicians and regulatory bodies to advance the role of medicinal cannabis in modern healthcare.



Authorised for release by Nan-Maree Schoerie, Managing Director

-ENDS-

Investors and Media

Tim Dohrmann, NWR Communications

P: +61 468 420 846

E: tim@nwrcommunications.com.au

About ECS Botanics Holdings Ltd

ECS Botanics Holdings Ltd (ASX: ECS) is an Australian medicinal cannabis cultivator and manufacturer located in Northwest Victoria. ECS utilises progressive and innovative cultivation methodologies to produce quality medicine in a sustainable way, adopting regenerative and organic horticultural practices and renewable energy sources. Licenced by the Australian Therapeutic Goods Administration to manufacture GMP (equivalent to PIC/S, EU agencies are all PIC/S members) certified products, ECS has become a leading provider of high quality, affordable medicinal cannabis.